


Q1 Please select the section you would like to consult:

swer Choices	Responses	
Section 1: Introductory Statements and Governance	8.26%	59
Section 2: Selection, Procurement and Distribution	7.98%	57
Section 3: Production and compounding	12.75%	91
Section 4: Clinical Pharmacy Services	37.68%	269
Section 5: Patient Safety and Quality Assurance	19.05%	13
Section 6: Education and Research	14.29%	10
Other	0.00%	(
al		714






er Choices	Responses
Case studies of hospital pharmacy practice in other European countries	48.31% 43
Developments in Hospital Pharmacy outside of Europe e.g. North America, Asia, Middle East, etc.	26.97% 24
Health Technology assessment (HTA).	25.84% 23
lorizon scanning conceptual issues of hospital pharmacist profession e.g. reforming hospital pharmacy for an ageing society	21.35% 19
Hospital pharmacy finance, management and administration issues	32.58% 29
Hospital pharmacy management	41.57% 37
nterfaces to various disciplines and professions	11.24% 10
Pharmacy and data mining	17.98% 16
nformation Technology (IT) solutions for hospital pharmacies (e.g., ERP-systems, Electronic Patient Record, production, tenders, order entry etc.)	26.97% 24


Total Respondents: 89		
Solving common problems in hospital pharmacy e.g. medicines shortages, finance, communication	26.97%	24
LEAN model applied to hospital pharmacy	26.97%	24

Q3 Which other section would you like to consult?




Answer Choices	Responses	
Section 2: Selection, Procurement and Distribution	11.11%	10
Section 3: Production and compounding	7.78%	7
Section 4: Clinical Pharmacy Services	11.11%	10
Section 5: Patient Safety and Quality Assurance	11.11%	10
Section 6: Education and Research	10.00%	9
EXIT SURVEY	48.89%	44
Total		90

Q4 Section 2: Selection, Procurement and Distribution




Answer Choices	Responses	
Barcoding and closed loop medication	44.64%	50
Drug shortages	45.54%	51
Cost of new treatments and budget constraints	52.68%	59
Introducing new technology into the hospital pharmacy*	46.43%	52
Selection and use of Medical Devices	24.11%	27
Total Respondents: 112		

Q5 Which other section would you like to consult?



nswer Choices	Responses	
Section 1: Introductory Statements and Governance	11.82%	13
Section 3: Production and compounding	20.91%	23
Section 4: Clinical Pharmacy Services	17.27%	19
Section 5: Patient Safety and Quality Assurance	18.18%	20
Section 6: Education and Research	15.45%	17
EXIT SURVEY	40.00%	44
otal Respondents: 110		




Q6 Section 3: Production and compounding

Answer Choices	Responses	
Analytics / Quality Control	26.71%	39
Automation of production	37.67%	55
Hospital pharmacy medicines production	57.53%	84
Introducing new technology into the hospital pharmacy*	43.84%	64
Oncology pharmacy issues*	46.58%	68
Ready to use drugs*	39.04%	57
Total Respondents: 146		

Q7 Which other section would you like to consult?


Answered: 146 Skipped: 644 Section 1: Introductory... Section 2: Selection,... Section 4: Clinical... Section 5: Patient Safe... Section 6: Education an... EXIT SURVEY 0% 20% 40% 50% 60% 70% 80% 90% 100% 10% 30%

nswer Choices	Responses	
Section 1: Introductory Statements and Governance	5.48%	8
Section 2: Selection, Procurement and Distribution	10.27%	15
Section 4: Clinical Pharmacy Services	17.81%	26
Section 5: Patient Safety and Quality Assurance	14.38%	21
Section 6: Education and Research	7.53%	11
EXIT SURVEY	44.52%	65
otal		146




Q8 Section 4: Clinical Pharmacy Services

EAHP Needs assessment survey 2016





Answer Choices	Responses	
Antimicrobial treatment	50.32%	155
Patients with chronic ilnesses and continuity of care	28.90%	89
Clinical pharmacy in Critical Care	32.79%	101
Conduct and results of clinical trials	10.39%	32
Dendritic cell therapy	6.82%	21
Drugs in pregnancy and lactation	18.18%	56
HIV transmission prevention	8.12%	25
Medication Reconciliation	34.42%	106
Computerized Physician Order Entry (CPOE) and Clinical Decision Support Systems (CDSS)	20.78%	64
Medicine adherence	25.00%	77
Medicines for children	23.70%	73
Medicines for older patients	27.60%	85
Pharmacotherapy updates	35.06%	108
Artificial nutrition (TPN and EN)	24.35%	75
Ocular disorder treatment	4.22%	13
Oncology pharmacy issues*	28.25%	87
Service and drug delivery to home patients	10.71%	33
Targeted therapy and immunotherapy	18.83%	58
New treatments in oncoematology	15.91%	49
Treatments for Hemophilia	5.19%	16
Off label use of medicines	25.97%	80
Wound healing	8.12%	2
Fotal Respondents: 308		






Answer Choices	Responses	
Section 1: Introductory Statements and Governance	3.20%	9
Section 2: Selection, Procurement and Distribution	6.41%	18
Section 3: Production and compounding	8.54%	24
Section 5: Patient Safety and Quality Assurance	25.62%	72
Section 6: Education and Research	18.86%	53
EXIT SURVEY	37.37%	105
Total		281






Responses	
35.77%	88
33.74%	83
28.86%	71
47.15%	116
58.54%	144
33.74%	83
14.63%	36
41.06%	101
19.51%	48
	19.51%






Inswer Choices	Responses	
Section 1: Introductory Statements and Governance	5.85%	12
Section 2: Selection, Procurement and Distribution	7.32%	15
Section 3: Production and compounding	8.29%	17
Section 4: Clinical Pharmacy Services	26.34%	54
Section 6: Education and Research	15.61%	32
EXIT SURVEY	36.59%	75
otal		205



Q12 Section 6: Education and Research

nswer Choices	Responses	
Academic training as continuing education tool	45.79%	87
Update on EU legislation on clinical trials and human research	17.37%	33
Distance learning, lifelong learning	34.74%	66
Patient centered learning	32.63%	62
Postgraduate training of HP and documentation of competencies	34.21%	65
Professional development issues e.g. sessions on improving communication skills, etc.	26.84%	51
Therapeutic education of the patient	40.53%	77
otal Respondents: 190		



Q13 Which other section would you like to consult?

nswer Choices	Responses	
Section 1: Introductory Statements and Governance	6.70%	12
Section 2: Selection, Procurement and Distribution	5.03%	9
Section 3: Production and compounding	7.82%	14
Section 4: Clinical Pharmacy Services	19.55%	35
Section 5: Patient Safety and Quality Assurance	12.85%	23
EXIT SURVEY	48.04%	86
otal		179